Germany-based Boehringer Ingelheim, one of the world's largest pharmaceutical companies, will use a recently established partnership to further expand operations in the Chinese market, the head of the company said in Shanghai on Tuesday, showing confidence in the Chinese market.
Chen Jining, secretary of the Shanghai Municipal Committee of the Communist Party of China, met with Chairman Hubertus von Baumbach and Eric Tse, CEO of Sino Biopharmaceutical Co, in Shanghai, according to an official statement.
During the meeting, Chen praised a recently established partnership formed by Boehringer Ingelheim and Sino Biopharmaceutical, and introduced the latest developments in Shanghai's biomedicine industry.
Shanghai regards biomedicine as one of three key industries to focus on, and offers support in the entire chain from research and development to production, as well as technological innovation and industrial development, Chen said, while extending a welcome to Boehringer Ingelheim and Sino Biopharmaceutical to establish more operations in Shanghai.
In April, Boehringer Ingelheim and Sino Biopharmaceutical announced a new strategic partnership that will focus on bringing innovative cancer therapies to the Chinese market, according to media reports.
